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Abstract: Inflammation is a hot topic in medical research, because it plays a key role in 
inflammatory diseases: rheumatoid arthritis (RA) and other forms of arthritis, diabetes, 
heart diseases, irritable bowel syndrome, Alzheimer’s disease, Parkinson’s disease, 
allergies, asthma, even cancer and many others. Over the past few decades, it was realized 
that the process of inflammation is virtually the same in different disorders, and a better 
understanding of inflammation may lead to better treatments for numerous diseases. 
Inflammation is the activation of the immune system in response to infection, irritation, or 
injury, with an influx of white blood cells, redness, heat, swelling, pain, and dysfunction of 
the organs involved. Although the pathophysiological basis of these conditions is not yet 
fully understood, reactive oxygen species (ROS) have often been implicated in 
their  pathogenesis. In fact, in inflammatory diseases the antioxidant defense system is 
compromised, as evidenced by increased markers of oxidative stress, and decreased levels 
of protective antioxidant enzymes in patients with rheumatoid arthritis (RA). An enriched 
diet containing antioxidants, such as vitamin E, vitamin C, β-carotene and phenolic 
substances, has been suggested to improve symptoms by reducing disease-related oxidative 
stress. In this respect, the marine world represents a largely untapped reserve of bioactive 
ingredients, and considerable potential exists for exploitation of these bioactives as 
functional food ingredients. Substances such as n-3 oils, carotenoids, vitamins, minerals 
and peptides provide a myriad of health benefits, including reduction of cardiovascular 
diseases, anticarcinogenic and anti-inflammatory activities. New marine bioactives are 
recently gaining attention, since they could be helpful in combating chronic inflammatory 
degenerative conditions. The aim of this review is to examine the published studies 
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concerning the potential pharmacological properties and application of many marine 
bioactives against inflammatory diseases. 
Keywords: inflammation; inflammatory diseases; marine bioactives; oxidative stress; 
reactive oxygen species; marine carotenoids; antioxidants 
 
1. Introduction  
Inflammation has different names in different parts of the body: rhinitis (inflammation of the nose), 
asthma (inflammation of the airways), arthritis (inflammation of the joints), dermatitis (inflammation 
of the skin), and so on. As the initial response that fires up the immune system, inflammation is the 
crucial first step in fighting infection and healing wounds. However, persistent inflammation and an 
immune system that is always activated, is known as chronic inflammation, leading to chronic disease. 
Inflammation also plays a role in heart disease [1], because the immune system attacks the “bad” 
cholesterol (LDL) incorporated in arterial walls. Ongoing inflammation eventually damages the 
arteries: it is so closely associated with heart disease that a test for inflammation called CRP   
(C-reactive protein) is used to assess cardiovascular risk, predicting the risk of Coronary Heart 
Disease (CHD) and stroke, together with cholesterol levels [2].  
For example, RA, a chronic progressive  autoimmune disease, characterized by erosive painful 
symmetric synovitis  with possible multisystem involvement, involves inflammation. In fact, some 
highly reactive transient chemical species, called reactive oxygen species (ROS), are involved in its 
pathogenesis, and pro-inflammatory cytokines, such as TNF-α and IL-1β, are implicated in the 
formation of toxic peroxynitrite by increasing the activity of nitric oxide synthase (NOS). The ROS 
trigger a cascade of events through NF-κB activation, which up-regulate gene expression of 
proinflammatory cytokines that activates immune responses, determining inflammation and cartilage 
damage [3].  
Inflammation has also been linked to diabetes. In type 1 diabetes, the immune system attacks the 
cells that make insulin; type II diabetes is also linked to inflammation, as chronic inflammation 
induces the release of TNF- α, which makes cells more resistant to insulin [4].  
In addition, even a link between inflammation and cancer exists: protein p100 allows 
communication between the inflammation and development processes, but in the case of chronic 
inflammation, the presence of too much p100 over-activates the developmental pathway, resulting  
in cancer [5]. 
Considering the involvement of phlogistics mediators, many inflammatory diseases could 
potentially be alleviated by dietary modification; diet may represent a potential therapeutic agent.  
Many reviews suggested that there is evidence of a protective effect of higher consumption of olive 
oil, fruits and vegetables, for example in developing RA, since dietary antioxidants effectively 
suppress the release of inflammatory cytokines by reducing ROS production [6]. The role of food in 
improving health has been recognized, activating the development of new classes of food, known as 
functional foods [7], which could decrease the risk of illness and the incidence or severity of chronic 
inflammatory disorders [8,9]. Numerous marine bioactives have been recently identified, whose Mar. Drugs 2012, 10  
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several biological activities could interfere with the pathogenesis of many diseases. It has already been 
shown that bioactive peptides isolated from fish protein hydrolysates, algal fucans, galactans and 
alginates possess anticoagulant, anticancer and hypocholesterolemic activities [10]. Fish oils and 
marine bacteria are known to be excellent sources of omega-3 fatty acids (whose importance in the 
treatment of arthritis has been extensively investigated [11,12], assessing their analgesic effects in joint 
pain), while seaweeds and crustaceans contain powerful antioxidants, such as carotenoids and phenolic 
compounds [13]. In this respect, new marine bioactives, such as COX inhibitors (Pacifenol, 
Epitaondiol and Stypotriol triacetate), marine steroids (Contignasterol, Xestobergesterol, Clathriol B), 
molecules interfering with NF-κB (Cycloprodigiosine, Hymenialdisine and Cycloamphilectenes), 
macrolides, peptides (Cyclomarins, Salinamides and Halipeptins), other metabolites (Scytonemin and 
Petrocortyne) and many antioxidant agents (phenols and marine carotenoids, such as astaxanthin, 
fucoxanthin) have been recently discovered and characterized, in order to assess their potential role in 
contrasting inflammatory diseases.  
2. Role of Oxidative Stress and Antioxidants in Inflammatory Diseases 
There is a close relationship between oxidative stress (OS) and  inflammation  in patients with 
inflammatory diseases. In most phlogistic conditions, macrophages and leukocytes are activated firstly, 
so that ROS are generated in excessive amounts, determining OS. Elevated level of ROS, such as 
superoxide anion,  nitric oxide (NO),  hydrogen peroxide and hydroxyl radical, in synovial fluid 
(generated by activated macrophages, monocytes, and granulocytes, as well as anoxic reperfusion 
reactions), plasma malondialdehyde (MDA) and degradation products of lipid peroxidation represent 
important characterizing factors of disease [6]. 
This is also demonstrated by increased  plasma  malondialdehyde (MDA) levels observed  in 
previously published reports as end products and an indirect indicator of increased ROS generation [14]. 
Furthermore, during chronic inflammation, even protective mechanisms increase to dangerous levels: 
higher concentrations of ROS cause substantial lipid peroxidation, leading to toxic tissue damage [15]. 
In addition, some antioxidant erythrocyte enzymes, such as glutathione peroxidase (GSH-Px), 
superoxide dismutase (SOD) and catalase (CAT) in RA patients have been shown to have lower 
activities than in healthy subjects [16].  
Previous investigations have also established a relationship between systemic markers of 
inflammation and serum beta-carotene levels, and that phlogistic conditions produce increased ROS 
and decreased antioxidant levels, which may worsen the symptoms of disorders such as RA, 
osteoarthritis and systemic lupus erythematosus [17,18]; some authors  implied a deficient level of 
vitamin E among causes of their development. Decreased serum concentrations of α-tocopherol, and  
β-carotene were suggested as possible risk factors [19]. To confirm this, vitamin E supplementation 
was shown to improve clinical symptoms of RA, probably by reducing the formation of prostaglandins 
during the phlogistic process [20]. In fact, the combination of standard RA treatment and antioxidants 
even increases serum GSH-Px activity with subsequent clinical improvement, including in joint pain 
and morning stiffness [21].  
Based on these reports, improvement in antioxidant status through a greater  intake of dietary 
antioxidants such as vitamin E, vitamin C, carotenoids (including β-carotene, β-cryptoxanthin, and Mar. Drugs 2012, 10  
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zeaxanthin) and phenols, may prevent RA development and help RA management. Circulating 
antioxidants are scavengers of free radicals (FRs), and may inhibit oxidative damage and lead to the 
abolition of inflammation [22,23]. They can not only alleviate symptoms by reducing disease-related 
OS, but can also ameliorate  the potential side-effects and reduce the risk of complications of 
pharmacological therapy (non-steroidal anti-inflammatory drugs and corticosteroids) such as 
gastrointestinal bleeding, bone loss and increased requirement of some nutrients. It was recently 
postulated that circulating antioxidants also have a role in the prevention of cardiovascular disease 
(CVD): C-reactive protein (CRP) and oxidized LDL-cholesterol concentrations, are inversely related 
to plasmatic concentrations of vitamin C, carotenoids and phenols [24–26]. Therefore, dietary 
antioxidants may be protective against the development of inflammatory disease [27]. 
3. Biology of Marine Natural Products: A Potential Anti-Inflammatory and Antioxidant 
Strategy? 
Most anti-inflammatory drugs used against inflammatory disorders are cyclooxygenase (COX) 
inhibitors. They usually exert analgesic effects: non-steroidal anti-inflammatory agents, such as aspirin 
and indomethacin, relieve pain by inhibiting the production of prostaglandins and decreasing the 
sensitivity of peripheral nociceptors [28]. The enzyme COX-1 is involved in the analgesic effect [29]; 
it produces prostaglandins, which protect the kidney and stomach from tissue and mucosal damage. 
Conversely, inhibition of COX-1 causes renal damage and gastric irritation, the typical side effects of 
aspirin-like drugs [30]. The other enzyme, COX-2, requires more time than COX-1 to form 
prostaglandins and contributes to the inflammation. However, among inflammation-related targets, we 
should consider not only COX, but also molecules able to interfere with factors involved in the 
modulation of gene expression, such as NF-κB, which could also act as potential anti-inflammatory 
agents [27]. In this respect, marine natural bioactives were recently shown to contain antioxidant 
agents, steroids and several novel molecular entities potentially able to target COX-1, COX-2 and the  
NF-κB pathway [31]. 
3.1. COX Inhibitors 
3.1.1. Pacifenol 
Pacifenol is a terpenoid isolated from seaweeds of the marine alga Laurencia claviformis, collected 
in Easter Island and belonging to the Rhodomelaceae family, whose structure was characterized by 
chemistry studies and crystallographic analysis in 1971 [32].  
The probable precursor of pacifenol, prepacifenol, was originally isolated from the Australian red 
alga Laurencia filiformis, but later, pacifenol was found naturally in Laurencia tasmanica as well [33]. 
This halogenated sesquiterpene represented the first example in chemical literature of a natural 
bioactive obtained from algae containing bromine and chlorine atoms covalently bound [34].  
However, these new metabolites, pacifenol and prepacifenol, were found not only in red alga, but 
also in some marine invertebrates, for example in the digestive system of the mollusk   
Aplysia californica [35].  Mar. Drugs 2012, 10  
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An antimicrobial activity of pacifenol derivatives has previously been reported, after testing against 
some microrganisms, especially against Pseudomonas aeruginosa and Streptococcus enteriditis. 
In addition, pacifenol exerts an inhibitory activity on inflammation by decreasing leukotriene B4 
(LTB4) and thromboxane B2 (TXB2) production, but also stopping degranulation response [36].  
In particular, its anti-inflammatory action, exercised through inhibition of the key enzyme 
phospholipase A2 and the consequent modulation of the cyclooxigenase pathway, and its anti-allergy 
effect, could be exploited to contrast the phlogistic processes implicated in the pathogenesis of many 
inflammatory and allergic diseases. 
3.1.2. Epitaondiol 
This terpenoid was isolated from seaweeds of Stypopodium flabelliforme, collected near Easter 
Island in the South Pacific Ocean [37]. The genus Stypopodium is a tropical group of brown algae, 
phaeophyceae, with rich components of polycyclic meroditerpenoids, possessing several biological 
activities [38]. Epitaondiol diacetate showed pharmacological effects in the rat cardiovascular   
system; a negative inotropic and chronotropic effect was noticed [39], but it also revealed marked  
anti-inflammatory effects through inhibition of eicosanoids (LTB4 and TXB2) release and modulation 
of the cyclooxigenase pathway. This happens through inhibition of the key enzyme phospholipase A2, 
which plays an important role in the release of arachidonic acid and the formation of lipid 
mediators [40]. Its anti-inflammatory activity is stronger than that of indomethacine [41].  
Epitaondiol also showed dose-dependent gastroprotective activity in mice gastric lesions, 
displaying similar action to lansoprazole [42].  
This double effect, both anti-inflammatory and gastroprotective, could be a fascinating treatment 
strategy without the well known side effects of drugs which are conventionally prescribed for the 
treatment of inflammatory diseases. 
In addition, epitaondiol exhibited antimicrobial effects against gram-positive and gram-negative 
bacteria, especially against E. faecalis [43], antiviral activity against herpes simplex [44], and 
antiproliferative properties: human colorectal adenocarcinoma and neuroblastoma cell line showed 
higher susceptibility [45]. In particular, 2beta-3alpha-epitaondiol possesses sodium channel blocking 
activity, a cytotoxic active against human lung cancer cells [46].  
Instead, the similar molecule called isoepitandiol showed a radical scavenging activity even more 
powerful than ascorbic acid [47].  
Both its powerful anti-inflammatory activity and this strong antioxidant effect deserve further 
studies, since they may be helpful in targeting the inflammation and oxidative stress that characterize 
many chronic inflammatory disorders. 
3.1.3. Stypotriol Triacetate 
This polycyclic meroditerpenoid [48], the complete configuration of which was recently   
determined [49], was also isolated from the seaweed Stypopodium flabelliforme. It is unstable in air, so 
that it had to be prepared by acetylation of the organic extract to avoid air oxidation in order to study 
its characterization and biological activities [50].  Mar. Drugs 2012, 10  
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Stypotriol displayed antifeedant and anti-inflammatory activity [51]. In particular, it exerts an 
inhibitory activity on inflammation by interfering with elastase release, by modulating the 
cyclooxigenase pathway through inhibition of phospholipase A2, and by decreasing the secretion of 
eicosanoids [40]. This may be useful in inhibiting inflammation and reducing elastase-induced 
cartilage degradation and articular damage, typical of RA and responsible of pain and loss of   
joint function. 
Similarly to epitaondiol, it showed antibacterial effects against gram-positive and gram-negative 
bacteria [43], and antiproliferative properties (human colorectal adenocarcinoma and rat basophilic 
leukemia cell line showed higher susceptibility) and was the most cytotoxic toward cancer cells with a 
concentration-dependent inhibitory effect, followed by epitaondiol [45]. 
3.2. Marine Steroids 
Steroids are synthetic drugs widely used for treating asthma, RA, psoriasis and a wide variety of 
inflammatory conditions. They work by decreasing inflammation and reducing the activity of the 
immune system; they provide significant relief from articular pain and stiffness, dyspnea, cutaneous 
manifestation and other phlogosis related symptoms. 
Marine organisms, in particular sponges, have recently been recognized as a notable source of 
uncommon steroids showing potent biological anti-inflammatory activities. 
3.2.1. Contignasterol 
This natural polyoxygenated steroid with a new side chain, isolated from the marine sponge 
Petrosia contignata in Papua New Guinea, has been the subject of many investigations, including both 
biological studies and synthetic work [52]. 
It belongs to steroid class but it has a particular chemical structure, because of the unusual set of 
functional groups, the details of which have been already published [53]. Study results have shown its 
potential value in the treatment of asthma and other inflammatory diseases [27]. In particular, it 
inhibits the release of histamine from human basophils and lung tissue and attenuates the contractile 
response to histamine, probably indirectly interacting with cellular signaling systems leading to the 
inhibition of phospholipase C activity [31], protecting in this way from bronchoconstriction [50].  
In addition, contignasterol showed an ability to inhibit platelet aggregation in response to their 
activating factor PAF, which is a local mediator of thrombotic events, and collagen exposure of 
vessels, suggesting anti-thrombolytic activity. As a consequence, the pharmacological potential of 
contignasterol could enable it to be used as a cardiovascular and antiallergic drug, in order to treat 
hemodynamic disorders involving platelets, hypertension or hypotension, thrombosis, asthma, allergic 
rhinitis, psoriasis, rashes, osteoarthritis and inflammation in general [54,55]. 
3.2.2. Xestobergsterol 
This pentacyclic polyhidroxylated steroid was isolated in 1992 from the Okinawan marine sponge 
Xestospongia bergquisita [56].  Mar. Drugs 2012, 10  
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It is a strong inhibitor of IgE-mediated histamine release from activated mast cells [57], with an 
inhibitory effect that is much more potent than the antiallergy drug disodium cromoglicate [53].  
In particular, Xestobergsterol A dose-dependently inhibited the generation of inositol triphosphate 
(IP3) and phospholipase C (PLC) activity and inhibits Ca
2+-mobilization from intracellular Ca
2+-stores, 
which are early events in IgE-dependent mediator release [58]. Xestobergsterol  has undergone a 
number of investigations, including synthetic work on its analogues [59]. 
So, like contignasterol, it could be considered a potential anti-asthma agent with a promising 
pharmacological potential [27].  
3.2.3. Clathriols  
Clathriols A and B are novel polyoxygenated steroids isolated from the marine sponge Clathria 
lissosclera, in New Zealand waters.  
They possess the rare and only naturally-occurring 14-beta-stereochemistry, a typical configuration 
of marine sponges [60]: This makes them structurally and biologically very similar to contignasterol, 
even if their biological action has turned out to be less powerful than contignasterol and its derivatives 
in blocking histamine release [27]. 
Both are not only light anti-allergy molecules, but also moderate anti-inflammatory compounds. In 
particular, the anti-inflammatory pharmacology of clathriol B was reported in 2000 [61]; however, 
further studies took place during 2003 [60] and more recently [62,63].  
Clathriol B inhibits the production of superoxide from human peripheral blood neutrophils [50], 
which is known to be implicated in the pathogenesis of inflammatory disorders: in this respect also 
clathriols should be studied in more depth, since they may also be helpful in alleviating the 
inflammation and oxidative stress that characterize several chronic degenerative diseases.  
3.3. Molecules Interfering with NF-κB 
3.3.1. Cycloprodigiosin 
This molecule belongs to the prodigiosin family, but here, the side chain is cyclized to form a  
six-membered ring [64]. Cycloprodigiosin is the red pigment produced by various marine bacteria, 
including  Serratia marcenses,  Zooshikella rubidus and  Pseudoalteromonas denitrificans, with 
immunosuppressive properties and apoptotic effects on cancer cells, interacting with p65 and the 
nuclear factor κB (NF-κB) pathway [65]. In particular, Cycloprodigiosin hydrochloride, produced by 
Pseudoalteromonas denitrificans, causes cytotoxic effects and apoptotic cell death in various 
cancerous cell lines, especially with the pro-inflammatory cytokine Tumor Necrosis Factor (TNFα). In 
fact, it suppresses NF-κB-dependent gene expression, while NF-κB activation is considered to promote 
survival in cells, inhibiting transcriptional activation [66]. In fact, cycloprodigiosin hydrochloride leads 
to apoptosis breast [67], liver and colon cancer cells, acting as a H+/Cl− symporter, inducing cytosolic 
acidification [68]. In addition, it resulted in being useful against promyelocytic leukemia, inducing cell 
differentiation or apoptosis through up-regulation of Fas ligand, activation of stress-activated protein 
kinase and caspase [69]. Inhibition of the NF-κB pathway disturbs the immune system, conferring both 
immunosuppressant and anti-tumor effects [70]. It is also an immunosuppressant agent because of its Mar. Drugs 2012, 10  
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action as a selective inhibitor of T cell proliferation, like other members of the prodigiosin family [71]. 
Cycloprodigiosin also stimulates nitric oxide production during hepatic injury, improving cell status by 
regulating the expression of NF-κB-dependent genes, such as inducible Nitric Oxide Synthase 
(iNOS) [72], Considering that immunosuppressive drugs such as corticosteroids and mesalazine can 
prevent the activation of NF-kappaB, both the suppression of NF-κB and increased NO production 
have been suggested as an anti-inflammatory strategy in inflammatory bowel disease (IBD), so that 
administration of cycloprodigiosine may limit chronic inflammation [73]. Since NF-κB is known to be 
a transcription factor regulating inflammatory response genes and implicated in AR, its inhibition 
could also indicate anti-inflammatory and anti-arthritic properties possessed by cycloprodigiosin [74]. 
3.3.2. Hymenialdisine 
This is an alkaloid isolated from marine sponges, such as Acanthella aurantica and Stylissa  
massa [75] and investigated for its properties against NF-κB activation, and its inhibitory effect on  
IL-8, IL-2 and TNF-α production. Hymenialdisine inhibits several proteins regulating cellular cycle 
and functions, such as glycogen synthase kinase-3beta, cyclin-dependent kinases, and casein kinase 1, 
by competing with ATP for binding to these kinases [76]. In this way, it also inhibits phosphorylation 
of the protein tau (which is hyperphosphorylated in Alzheimer’s disease) with promising potential 
against human neurodegenerative diseases [77], and NF-κB activity, probably by inhibiting both 
protein kinase C and I-kB phosphorylation [78]: molecules able to interfere with factors involved in 
the modulation of gene expression, such as NF-κB, can also be considered as potential anti-inflammatory 
agents. Its anti-inflammatory properties have also been reported, achieved through its ability to 
decrease IL-8 [79] and IL-1beta production [80]. 
In addition, hymenialdisine was tested on bovine articular cartilage, also evaluating its inhibitory 
effect on proteoglycan degradation in a dose-dependent manner [81]. A potential inhibitory effect on 
proteoglycan degradation should be investigated on human cartilage and articular damage, typical   
of RA. 
3.4. Marine Macrolides 
These are class of highly oxygenated natural products, whose structure is characterized by a 
macrocyclic lactone. The first marine macrolides were the aplysiatoxins, reported in 1974 as toxic 
constituents of the sea hare Stylocheilus longicauda. At present, more than 200 marine macrolides 
have been discovered, paying attention to their biological active properties, such as 
immunomodulation, cytotoxic, anticancer, antiviral, and antifungal [82]. Marine macrolides exert 
antiproliferative cytotoxic activity with various molecular targets [83], representing a promising 
potential agent in anticancer research [84]. For example, lobophorins A and B are two bioactives with 
antibiotic, anticancer and anti-inflammatory properties, even stronger than indomethacin [85], and 
isolated from marine actinomycetes found in the Caribbean brown alga Lobophora variegata; 
latrunculins A and B are architecturally novel molecules isolated from the Red Sea sponge Latrunculia 
magnifica, which also affect cellular growth through disrupting actin polymerization and 
microfilament organization with antiproliferative effects [86]; aplyronines, isolated from the sea hare 
Aplysia kurodai [87]; dolastatin 19, recently obtained from the sea hare D. auricularia from the Gulf Mar. Drugs 2012, 10  
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of California, which displayed antiproliferative activity, in particular in breast and colon cancer 
cells [88]; scytophycins, extracted from the blue and green algae Scytonema pseudohofmanni [89], and 
sphinxolides obtained from the New Caledonian marine sponges Neosiphonia superstes [90]: They are 
also actin-binding natural products, able to inhibit the proliferation of human cancer cell lines [91]. In 
conclusion, macrolides have promising potential, both in anticancer and in rheumatologic research 
therapy, in terms of their cytotoxic, immunosuppressant and anti-inflammatory properties. 
3.5. Peptides 
3.5.1. Cyclomarins 
Cyclomarins are three cyclic heptapeptides (A, B and C), isolated from the marine bacterium 
actinomycete, belonging to Streptomyces sp., along the Californian coast.  
Marine actinomycetes have been exploited as a source of biologically active secondary metabolites 
with antibacterial and anticancer properties [92].  
Some molecules have also been reported to be anti-inflammatory, such as cyclomarins and 
salinamides [93]. 
Cyclomarin A, constituted of three common and four unusual aminoacids, showed potent   
anti-inflammatory and antiproliferative activities in both in vivo and in vitro assays, managing to 
inhibit edema and pain similarly to the drug hydrocortisone [94]. 
This molecule also displayed an ability to kill Mycobacterium tuberculosis by targeting its 
caseinolytic protease, resulting in a promising component of antitubercular drugs [95]. 
A moderate anti-inflammatory effect has been reported also in cyclomarin C, whose total synthesis 
was recently experimented and reported [96]. 
For this reason both cyclomarin A and C, and their derivatives, can develop as a potential naturally 
occurring anti-inflammatory therapies. 
3.5.2. Salinamides 
These five peptides (A, B, C, D and E) were isolated, like cyclomarin, from marine actinomicetes, 
belonging to Streptomyces sp., isolated from the surface of the jellyfish Cassiopea xamachana, found 
in Florida waters [93].  
Salinamide A and B are the two major bicyclic metabolites, with potent topical anti-inflammatory 
activity and moderate antibiotic activity against gram-positive bacteria, and could be used in the 
treatment of tissue inflammation and some infections [97].  
Salinamides C, D and E are the minor metabolites, whose structure was established through spectral 
and chemical techniques: salinamide D has a similar structure but contains a valine residue in   
place of the isoleucine present in salinamide A; salinamides C and E are represented by monocyclic 
peptides, which exert a light anti-inflammatory activity [98], being potentially able to combat   
inflammatory diseases. Mar. Drugs 2012, 10  
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3.5.3. Halipeptins 
These new four metabolites (A, B, C and D) were isolated from the marine sponge Haliclona, 
found in the waters of Vanuatu. Halipeptins are made up of a peptidic portion, conventional alanine 
residues and unusual residues, assembled in a 17-membered macrolactone ring [99]. 
Particular attention has been focused on halipeptin A, because of its potent biological activities. 
Halipeptin A is a cyclic depsipeptide, whose total synthesis has been successfully carried out [100], 
together with recent syntheses of halipeptin D and its analogues, in order to take advantage of their 
biological properties [101]. 
It was found to possess a strong anti-inflammatory activity, both in vivo and in vitro, even stronger 
than the classical anti-inflammatory drugs, naproxene and indomethacin [102], resulting in an ability 
to inhibit edema in mice [99]: this powerful antiphlogistic action is similar to conventional drugs  
but without their typical side effects, and could be the basis of a beneficial strategy against   
inflammatory disorders. 
3.6. Other Metabolites 
3.6.1. Petrocortynes 
These new lipidic compounds, polyacetylenic alcohols, isolated from marine sponges Petrosia [103], 
were collected from Keomun Island, along the Korean coast [104].  
Petrocortyne A showed cytotoxic activity against solid tumor cells and anti-inflammatory activity 
inhibiting macrophages, decreasing TNF-alpha production and the expression of migration cell factors 
involved in phlogistic infiltration [105]. As a consequence, it blocks cellular inflammatory processes 
and immune cell migration to inflamed tissue; this interferes with the immunopathology of acute or 
chronic inflammatory and autoimmune diseases, such as septic shock, or rheumatoid arthritis, or even 
multiple sclerosis, where the pro-inflammatory cytokine TNF-α is widely involved [106]. In addition, 
not only anti-inflammatory, but also pro-aggregative effects of petrocortyne A have been investigated 
in vitro, establishing that this molecule induces weak intracellular pro-aggregative signals [105–107]. 
Petrocortyne D, E , F , G and H , whose structures were determined through chemical and   
spectral methods, exhibited moderate cytotoxicity and inhibitory activity against the enzyme   
phospholipase A2 [104]. 
3.6.2. Scytonemin 
This alkaloid has an unusual dimeric structure, firstly elucidated in 1993 [108], which can be 
considered unique among natural products [109]. 
It was isolated from Cyanobacteria, is a yellow to brown, lipid-soluble pigment [110], extracted 
from the terrestrial  alga,  Nostoc commune vauch  [111].  Scytonemin seems to be an inhibitor of   
polo-like kinase 1 (an enzyme implicated in G2/M transition during the cell cycle) and of   
platelet-derived growth factor-induced rheumatoid synovial fibroblast.  
In addition, T cells treated with scytonemin were induced to apoptosis, so that it could be developed 
and used for the treatment of hyperproliferative disorders [109]. Besides this antiproliferative and  Mar. Drugs 2012, 10  
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anti-inflammatory activity, Scytonemin also showed considerable antioxidant activity, so that it could 
be an interesting therapeutic agent [111] against degenerative anti-inflammatory diseases. 
4. Antioxidant Agents 
Current dietary guidelines in chronic diseases prevention, including cancer and CHD, recommend 
an increased intake of fruit and vegetables, which are rich sources of antioxidants [112] and have a 
wide range of antiatherogenic properties [113–115].  
Antioxidants, carotenoids in particular, protect cellular components against oxidative damage, but 
they have even a role in regulating gene expression and in inducing cell-to-cell communications [116]. 
Carotenoids are ubiquitously present in nature, existing in plants, algae and microorganisms; they are 
able to bind heavy metals and toxic substances, such as arsenic, preventing their accumulation in 
human organisms [117,118]. However, humans and other animals are not able to manufacture 
carotenoids and require them as part of their diets. There are two classes of carotenoids: carotenes and 
xanthophylls [119]. Astaxanthin and fucoxanthin are major marine carotenoids, which show strong 
antioxidant activity, attributed to quenching single oxygen atoms and scavenging free radicals [120]. 
4.1. Astaxanthin  
This is the main  carotenoid  pigment, related to the other well-known carotenoids, β-carotene, 
zeaxanthin and lutein,  found  in  algae (the chlorophyte alga, Haematococcus pluvialis, seems to 
accumulate the major quantity of astaxanthin in nature) and aquatic animals, present in many popular 
seafoods (trout, salmon, shrimp, lobster and fish roe) [121]. Astaxanthin contains two additional 
oxygenated groups on each ring structure compared with other carotenoids, resulting in more powerful 
antioxidant activities. Its  antioxidant property  has been demonstrated in several studies: in some 
cases,  it was  shown to possess even stronger free radical  scavenging and antioxidant activity 
than vitamin E and β-carotene [122]. It has several essential biological functions: protection against 
UV light effects, inflammation, aging and age-related diseases, and the promotion of the  immune 
response in the liver, kidney, heart, eyes and joints. It promotes prostate health, protects membranous 
phospholipids and other lipids from peroxidation [123], and has also been associated with shifts in 
inflammation response [124]. Clinical studies have also demonstrated reductions in the cardiovascular 
risk markers of oxidative stress and inflammation, as well as improved blood status [125,126]. 
Because of its antioxidant and membrane preservation properties, astaxanthin has a considerable 
potential in the prevention and treatment of various chronic inflammatory disorders, such as   
cancers, AR, metabolic syndrome, diabetes, diabetic nephropathy, and gastrointestinal liver and 
neurodegenerative diseases [127], and could provide benefits not only for the cardiovascular system, 
but also in other inflammatory disease. Therefore, its daily consumption is a practical and beneficial 
strategy in human health management [128].  Mar. Drugs 2012, 10  
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4.2. Fucoxanthin 
Fucoxanthin is brown pigment belonging to the class of xanthophylls, with antioxidant   
properties [129] under anoxic conditions, whereas other carotenoids have practically no quenching 
abilities, donating electrons as a part of its free-radical quenching function [130].  
During normal metabolism, the body produces heat: Fucoxanthin affects many enzymes involved  
in fat metabolism determining an increase in the release of energy from fat [131], thus an increase  
of thermogenesis.  
Fucoxanthin is a powerful antioxidant that protects cells from oxidative damage and providing 
other health benefits: improved cardiovascular health, reduction of inflammation, cholesterol and TG 
levels, improvements in blood pressure levels, and healthy liver function [132–134].  
Future clinical studies will determine the effectiveness of these marine carotenoids (astaxanthin and 
fucoxanthin) not only on the vascular structure, but also on cartilage and joint health in at-risk patients 
or in those with established osteoarthritis. 
5. Conclusion 
The sea is a rich source of useful compounds with new chemical structures and pharmacological 
effects: significant immunomodulation (against allergy), anti-inflammatory (and as a consequence, 
antitumor and analgesic), antibacterial and antiviral activities [135]. In particular, brown seaweeds 
contain at the same time many types of bioactives, such as omega-3 polyunsaturated fatty acids 
(PUFAs), polyphenols, fucosterol, and carotenoids. Algal polyphenols possess many biological 
activities, including anti-inflammatory, hepatoprotective, anti-tumor, anti-hypertensive and HIV-1 
reverse transcriptase activities, as well as anti-diabetic activity, based on the inhibition of   
α-glucosidase [136]. New marine bioactives, such as COX inhibitors, marine steroids, molecules 
interfering with NF-κB, macrolides, peptides and many antioxidant agents, could be helpful in treating 
chronic inflammatory degenerative conditions. Improvement in antioxidant status, through a 
greater intake of both terrestrial and marine antioxidants, may prevent the development and help the 
management of inflammatory diseases: circulating antioxidants are scavengers of FRs and may inhibit 
oxidative damage and lead to the elimination of inflammation. They can not only alleviate symptoms, 
by reducing disease-related OS, but also tackle the potential side effects of pharmacological therapy, 
reducing the risk of complications. 
The superiority of marine peptides, marine carotenoids, and marine polyphenols, as compared to 
analogue terrestrial resources, can be explained because of the simultaneous presence in seaweeds of a 
wider variety of these substances: Their positive actions are synergistic, and so more powerful, as 
compared with those from terrestrial origins.  
Marine bioactives could potentially develop as functional food, since their biological activities 
appear to influence the pathogenesis and the clinical course of several inflammatory diseases [137]. 
Consequently, research should move towards further study and the development of marine functional 
foods in the hope that, in the future, their regular introduction into the human diet could lead to a 
reduction in the incidence and severity of many disorders [13]. Considering the lengthening of life 
expectancy, our eating habits will be crucial in promoting human health. Further research should go in Mar. Drugs 2012, 10  
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this direction in order to show new preventive and potential therapeutic strategies against several 
inflammatory chronic diseases [138]. 
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